Responses to mepolizumab in real world treatment of severe asthma
| ISRCTN | ISRCTN15239412 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN15239412 |
| Sponsor | Karolinska University Hospital Stockholm, part of Region Stockholm County Council |
| Funder | Academic funds and investigator-initiated industry support (GSK) |
- Submission date
- 13/11/2026
- Registration date
- 16/11/2026
- Last edited
- 16/11/2026
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Respiratory
Plain English summary of protocol
Background and study aims
Mepolizumab has been introduced as biologic treatment for severe asthma targeting the cytokine IL-5 that drives part of the eosinophilic inflammation being a key feature in asthmatic inflammation. Although clinical trials during the drug development process have established that many patients with severe asthma respond well to this new treatment, it remains to determine which patients in a real-life clinical setting respond favourably to mepolizumab and which factors that determine the responsiveness. This study is focused on improved methods to assess the clinical response and new predictive biomarkers to aid precision medicine decisions.
Who can participate?
Males and females aged 18 years or older with severe asthma diagnosed in the specialist care setting. Everyone must give written informed consent before taking part.
What does the study involve?
Patients who have been selected for treatment with mepolizumab by the clinical severe asthma team are after the decision has been made invited to participate in the research project. After consent has been obtained, a thorough medical history, extensive clinical examinations and collection of samples for biochemical and immunological measurements of markers in blood, urine, saliva and exhaled air are performed at baseline before the start of the treatment with mepolizumab. The majority of examinations and samplings are repeated after 4 months, 1 year, 2 years and 3 years on the treatment. At all visits, the patients also report symptoms and quality of life measures by the use of standardised questionnaires.
What are the possible benefits and risks of participating?
There is no direct benefit to participate in the research project above the potential benefit of improved asthma due to the effects of the treatment decided on clinical grounds. However, the information collected may help improve future diagnosis and treatment of asthma for similar patients. In addition, it is our experience from previous projects that patients who participate in this type of research with long study visits and prolonged follow-up visits learn much about their condition and thereby improve self management.
The risks are small and would relate to giving different biological samples (blood, urine, saliva and exhaled breath), such as e.g. brief discomfort or bruising during sampling of blood.
Where is the study run from?
The study is carried out at the Departments of Lung and Allergy Diseases at the Karolinska Hospital in Stockholm and the Academic Hospital in Uppsala, both centres in Sweden.
When is the study starting and how long is it expected to run for?
June 2017 to September 2025.
Who is funding the study?
Academic funds and investigator-initiated industry support (GSK).
Who is the main contact?
Prof. Sven-Erik Dahlén, sven-erik.dahlen@ki.se
Contact information
Principal investigator, Scientific, Public
Lung and Allergy Research Unit (CLARU), C2:88
Department of Medicine Huddinge, Karolinska Institutet
Karolinska University Hospital Huddinge
Hälsovägen
Stockholm
14186
Sweden
| 0000-0002-4993-4002 | |
| Phone | +46 706 207 442 |
| sven-erik.dahlen@ki.se |
Study information
| Primary study design | Observational |
|---|---|
| Observational study design | Cohort study |
| Scientific title | The BIOCROSS cohort for real-world assessment of biomarkers and clinical responses to mepolizumab in severe eosinophilic asthma |
| Study acronym | BIOCROSS-MEPO |
| Study objectives | 1. To test a new composite scoring system (COMSA) for grading of the clinical response to the treatment 2. To determine which baseline biomarkers before treatment that predict short-term as well as long term clinical outcomes 3. To determine response biomarkers that provide quantitative objective measures of target engagement, treatment effectiveness, and mechanisms of action |
| Ethics approval(s) |
Approved 16/06/2017, Regional Ethics committee in Stockholm, Sweden, decision registration no 2017/832-31/1 (Karolinska Institutet, Stockholm, SE-17177, Sweden; +46 852486000; epm@etikprovning.se), ref: 2017/832-31/1 |
| Health condition(s) or problem(s) studied | Severe eosinophilic adult asthma |
| Methodology | Patients who have been selected for treatment with the anti-IL5 biologic mepolizumab by the clinical severe asthma team are after the decision has been made invited to participate in the research project. After consent has been obtained, a thorough medical history, extensive clinical examinations and collection of samples for biochemical and immunological measurements of markers in blood, urine, saliva and exhaled air are performed at baseline before the start of the treatment with mepolizumab. The majority of examinations and samplings are repeated after 4 months, 1 year, 2 years and 3 years on the treatment. At all visits, the patients also report symptoms and quality of life measures by the use of standardised questionnaires. |
| Intervention type | Drug |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Mepolizumab (Nucala ®) 100 mg subcutaneously every fourth week during three years of follow-up |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
|
| Completion date | 15/09/2025 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 100 Years |
| Sex | All |
| Target sample size at registration | 80 |
| Total final enrolment | 78 |
| Key inclusion criteria | 1. Men and women above age of 18 years 2. General: Able to give written informed consent and able to read, comprehend, and write at a sufficient level to complete study related materials 3. Severe asthma: Meeting internationally recognised criteria for diagnosis of severe asthma including to have been under the follow up of a respiratory specialist for at least 6 months prior to enrolment in the study. During this time appropriate investigations should have been performed to exclude other diagnoses and steps taken to optimise asthma control including treatment of co-morbidities, assessment of adherence, and reduction in allergen exposure in sensitised subjects |
| Key exclusion criteria | 1. Subject has changed asthma medication within the 4 weeks prior to screening (except those using the Symbicort maintenance and reliever therapy) 2. Subject had a severe asthma exacerbation (requiring high dose OCS or a doubling of maintenance OCS for at least 3 days) in the previous month 3. Significant alternative diagnoses that may mimic or complicate asthma, in particular dysfunctional breathing, panic attacks, and overt psychosocial problems (if these are thought to be the major problem rather than in addition to severe asthma) 4. Significant other primary pulmonary disorders in particular pulmonary embolism, pulmonary hypertension, interstitial lung disease and lung cancer 5. Subjects with emphysema and bronchiectasis should only be excluded if this is thought to be the major pulmonary disorder rather than in addition to severe asthma 6. Diagnosis or current investigation of occupational asthma 7. Diagnosis of chronic inflammatory diseases other than asthma (inflammatory bowel disease, rheumatoid arthritis) 8. Alcohol or narcotic abuse |
| Date of first enrolment | 27/06/2017 |
| Date of final enrolment | 31/12/2024 |
Locations
Countries of recruitment
- Sweden
Study participating centre
Department of Medicine Huddinge, Karolinska Institutet
Karolinska University Hospital Huddinge
Hälsovägen
Stockholm
SE-14186
Sweden
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol file | version 3.0 | 05/10/2019 | 16/11/2026 | No | No |
Additional files
- 50646 BIOCROSS-Protocol_v3.0_05Oct2019.pdf
- Protocol file
Editorial Notes
16/11/2026: Trial's existence confirmed by Regional Ethics committee in Stockholm, Sweden.